If you have been reading about melanocortin signalling and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-06. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
Cold Case Investigation Units TELEMASP Bulletin, Texas Law Enforcement Management and Administrative Statistics Program Wagner, Adam (2012-01-04). "Why Stephen Lawrence's killers were sentenced as juveniles". The Guardian. Retrieved 2012-01-04. – explains sentencing in the UK, for cases that took place long ago.
=== Promotion in the United States === In 1977, the Associated Press delivered the first news story in the United States about powdered alcohol, which was then an unprecedented product. Investors were quoted as saying that they "hope[d] to revolutionize the liquor business with a product that's easy to carry, cheap and potent". A test sale of powdered alcohol, called "SureShot", was done in the United States.
=== EC 2.7.11: Protein-serine/threonine kinases === EC 2.7.11.1: non-specific serine/threonine protein kinase EC 2.7.11.2: [pyruvate dehydrogenase (acetyl-transferring)] kinase EC 2.7.11.3: dephospho-(reductase kinase) kinase EC 2.7.11.4: (3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)) kinase EC 2.7.11.5: [isocitrate dehydrogenase (NADP+)] kinase EC 2.7.11.6: [tyrosine 3-monooxygenase] kinase EC 2.7.11.7: myosin-heavy-chain kinase EC 2.7.11.8: Fas-activated serine/threonine kinase EC 2.7.11.9: Goodpasture-antigen-binding protein kinase EC 2.7.11.10: IkB kinase EC 2.7.11.11: cAMP-dependent protein kinase EC 2.7.11.12: cGMP-dependent protein kinase EC 2.7.11.13: protein kinase C EC 2.7.11.14: rhodopsin kinase EC 2.7.11.15: β-adrenergic-receptor kinase EC 2.7.11.16: G-protein-coupled receptor kinase EC 2.7.11.17: Ca2+/calmodulin-dependent protein kinase EC 2.7.11.18: myosin-light-chain kinase EC 2.7.11.19: phosphorylase kinase EC 2.7.11.20: elongation factor 2 kinase EC 2.7.11.21: polo kinase EC 2.7.11.22: cyclin-dependent kinase EC 2.7.11.23: [RNA-polymerase]-subunit kinase EC 2.7.11.24: mitogen-activated protein kinase EC 2.7.11.25: mitogen-activated protein kinase kinase kinase EC 2.7.11.26: tau-protein kinase EC 2.7.11.27: [acetyl-CoA carboxylase] kinase EC 2.7.11.28: tropomyosin kinase EC 2.7.11.29: low-density-lipoprotein receptor kinase EC 2.7.11.30: receptor protein serine/threonine kinase EC 2.7.11.31: [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase EC 2.7.11.32: [pyruvate, phosphate dikinase] kinase EC 2.7.11.33: [pyruvate, water dikinase] kinase
Sources: en.wikipedia.org
Elexacaftor and tezacaftor act as CFTR correctors to repair F508del processing by binding to the CFTR protein to increase the availability of CFTR protein on the cell surface. They work by modulating the position of the CFTR protein into the right position on the cell surface. Elexacaftor binds at a different site than tezacaftor. The combination of increased CFTR protein in the correct position on the cell surface with ivacaftor's potentiation of chloride channel opening results in increased transport of chloride and thinned mucus secretions.
Everyone has the right to food and water, and under the Charter of Fundamental Rights of the EU "the improvement of the quality of the environment must be integrated into the policies of the Union". The Common Agricultural Policy's origins lay in ensuring that all farm workers had fair wages and everyone had food, since in 1960 a third of employment and a fifth of GDP was in agriculture, and after WW2 Europe had been on the brink of starvation. In 2020, the agricultural workforce was 4.2% of the EU total. The CAP's objectives are still to increase production, "a fair standard of living for the agricultural community", to stabilise markets and supplies, and "reasonable prices" for consumers. In 2021, the CAP was 33.1% of the entire EU budget, at €55.1 billion, however there are no requirements for subsidies to be used so that farm workers (as opposed to owners) have fair pay scales, few requirements for rural development, and minimal standards for environmental improvement.
=== Skin === One form the rashes take is called "heliotrope" (a purplish color) or lilac, but may also be red. It can occur around the eyes along with swelling, but also occurs on the upper chest or back what is called the "shawl" (around the neck) or "V-sign" above the breasts and may also occur on the face, upper arms, thighs, or hands. Another form the rash takes is called Gottron's sign, which is red or violet, sometimes scaly, slightly raised papules that erupt on any of the finger joints (the metacarpophalangeal joints or the interphalangeal joints). Gottron's papules may also be found over other bony prominences including the elbows, knees, or feet. All these rashes are made worse by exposure to sunlight, and are often very itchy, painful, and may bleed. If a person exhibits only skin findings characteristic of DM, without weakness or abnormal muscle enzymes, may be classified as having amyopathic or clinically amyopathic dermatomyositis (ADM), formerly known as "dermatomyositis sine myositis".
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.